TREATMENT WITH VIVITROL TO REDUCE SELF-BITING BEHAVIOR IN ADULT RHESUS MACAQUES

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 前言：自我伤害行为(SIB)可以被定义为任何导致组织损伤的自我导向行为。这种情况发生在大约5%-13%的圈养恒河猴种群中，自咬是这种行为的最常见表现。此外，SIB是一个重大的人类健康问题，有趣的是，它发生在4%的普通公众中。目前，还没有广泛接受的治疗人类或非人类灵长类SIB的方法。然而，对人类和非人类灵长类动物的研究表明，用于治疗酒精中毒和药物滥用的治疗药物，如口服盐酸纳曲酮，在减少SIB的发生方面是有效的。到目前为止，还没有研究检验Vivitrol的价值，Vivitrol是一种长效的30天注射纳曲酮，用于治疗人类或非人类灵长类SIB。将Vivitrol用于SIB的一项重点研究可能开启Vivitrol在研究机构和普通公众中的新用途的探索。方法：共有20只成年恒河猴(Macaca Mulatta)有记录的自伤行为，将被分配到两组之一。 第1组(n=16)：在前四周的治疗阶段，将观察基线行为，并根据已建立的行为图进行编码。两次注射Vivitrol将在注射之间间隔四周。将对行为进行观察和编码。每次注射Vivitrol时将采集血样，每隔7天采集一次血样，直到研究结束进行治疗范围数据分析，最后阶段将是第二个基线行为观察和编码期。第2组(n=4)：分别于0、2、8小时、1、5、7、10、14、17、21、25、28天采血进行药代动力学研究。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Introduction: Self-injurious behavior (SIB) may be defined as any self-directed behavior that results in tissue injury. The condition occurs in approximately 5-13% of the captive rhesus macaque population with self-biting being the most common expression of the behavior. Additionally, SIB is a significant human health problem, which interestingly occurs in 4% of the general public. Currently, there are no widely accepted treatments for human or nonhuman primate SIB. However, studies with human and nonhuman primates have shown that therapeutic drugs used to treat alcoholism and drug abuse, such as oral naltrexone hydrochloride, are effective in reducing the occurrence of SIB. To date, there have been no studies examining the value of Vivitrol, a long-acting 30 day injectable naltrexone, for the treatment of human or nonhuman primate SIB. A focused study using Vivitrol for SIB may open the exploration of a novel use for Vivitrol in both research facilities and the general public. Methods: A total of twenty adult rhesus macaques (Macaca mulatta) with documented self-injurious behavior will be assigned to one of two groups. Group 1 (n=16): In the first four week treatment phase baseline behavior will be observed and coded according to an established ethogram. Two injections of Vivitrol will be administered with a four week interval between injections. Behavior will be observed and coded. Blood samples will be taken at the time of each Vivitrol injection and at seven day intervals until the end of the study for therapeutic range data analysis The final phase will be a second baseline behavior observation and coding period. Group 2 (n=4): A pharmacokinetic study will be performed with blood sampling occurring at 0, 2, and 8 hours and 1, 5, 7, 10, 14, 17, 21, 25, and 28 days.